Replies to post #14329 on Algernon Pharmaceuticals Inc (AGNPF)

[GVX808]

Great questions, that I am also asking myself.

However, the answer can be found in the last sentence of the press release:

"We look forward to completing our data review and receiving feedback from the U.S. FDA.”

Yesterday's incomplete news was released in order to get something to investors under the wire. It seems to me they also probably received the data in the 11th hour.
Chris Moreau knew he needed to get something to investors before April 1st, so they released the highlights and kept it very conservative:

- 0% mortality versus a 3.3% mortality rate in the control arm.

- 100% of patients in the 20 mg dose treatment arm with low blood oxygen level (SpO2 <94%) returned to normal levels of oxygen at day 4 versus day 9 for patients in the untreated arm.

- Strong trend of reduced ICU time was observed in the treatment arm versus the control arm.

- Furthermore, only 20mg is needed to arrive at those results. It's impossible to improve upon 0% and 100%, therefore 40mg is not needed (i.e. no improvement possible).


Unfortunately, for us, Chris Moreau's style is pretty conservative. He does not hype Ifenprodil to gain share price like some CEO's. Good or bad? It's hard to say. Probably just covering his a55.
I'm sure we all, me included, wanted to see mention of an EUA application.
Unfortunately, we just need to be a little more patient.

To answer your question:

This is the most important information that Algernon has to report to date and it’s delivered on their website? What happened to the Facebook Live events with explanations and discussions!?!?

Once again...
"We look forward to completing our data review and receiving feedback from the U.S. FDA.”

They just received the data... so I guarantee there is a ton of stuff going on behind the scenes:
- EUA application
- Working to find funding for an EUA and Phase III (government, private investors, etc)
- Maybe they are being contacted by big pharma... etc.

I think once they finish their data review with the FDA we will see plenty of interviews, explanations, and discussions.

...and you other question:

Why are they wasting time with a safe proven product that could be saving lives?!
Extremely difficult to stand by and wonder why?!?!

Once again, when they finish their data review with the FDA, I fully expect an EUA.

JMO. GLTA!